U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
You may also be interested in...
U.K Drug-Repurposing Program Expands, Attracts Industry Support
Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology
The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.